RBC Capital Sticks to Their Hold Rating for Akamai (AKAM)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jaluria covers the Technology sector, focusing on stocks such as Salesforce, Microsoft, and Pegasystems. According to TipRanks, Jaluria has an average return of -9.3% and a 45.60% success rate on recommended stocks.
Currently, the analyst consensus on Akamai is a Hold with an average price target of $92.55.
AKAM market cap is currently $11.5B and has a P/E ratio of 26.54.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 minutes ago
- Globe and Mail
COIN to Report Q2 Earnings: Will Higher Trading Volume Fuel Growth?
Coinbase Global COIN is set to report second-quarter 2025 results on July 31, after market close. This company beat estimates in three of the last four reported quarters and matched in one. Let's discuss the factors that are likely to be reflected in the upcoming quarterly results. Trading volume in the second quarter is likely to have improved owing to increased asset volatility and improved crypto asset prices. Crypto trading remains a major revenue driver for COIN. It has been prioritizing crypto utility by investing in infrastructure and foundational platforms. Increased market share in the U.S. spot and derivatives markets and an expanded product portfolio and international market presence are likely to have added to the upside. The company is likely to have benefited from the acquisition of Deribit, the world's leading crypto options exchange, in the quarter. This makes Coinbase the leading crypto derivative platform globally by open interest. The Zacks Consensus Estimate for total trading volume is pegged at 249 million, indicating an improvement of 10.1% from the year-ago reported number. The consensus estimate for total volume - Consumer is pegged at 46.1 million, suggesting a 25% increase from the year-ago reported number. The consensus mark for total volume - Institution is pegged at 203 million, indicating a surge of 7.4% from the year-ago reported number. Transaction revenues are likely to have benefited from higher fees for Consumer and Institutional. The Zacks Consensus Estimate for transaction revenues is pegged at $759 billion, indicating an increase of 23% from the year-ago reported figure. The Zacks Consensus Estimate for transaction revenues - Consumer is pegged at $647 million. The consensus estimate for transaction revenues - Institutional is pegged at $54 million. Revenues are likely to have benefited from market share gains in U.S. spot and derivatives trading, along with increased volumes in custody, staking and USDC assets, as well as growth in Coinbase One subscriptions. What Our Quantitative Model Predicts Our proven model predicts an earnings beat for Coinbase this time around. This is because the stock has the right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), which increases the odds of an earnings beat. Earnings ESP: Coinbase's Earnings ESP is +12.05%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: Coinbase currently has a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank stocks here. Other Stocks to Consider Euronet Worldwide EEFT has an Earnings ESP of +2.53% and a Zacks Rank of 2 at present. The Zacks Consensus Estimate for second-quarter 2025 earnings is pegged at $2.63 per share, indicating an increase of 16.9% from the year-ago reported figure. EEFT's earnings beat estimates in only one of the last four quarters, met in two and missed in one. Houlihan Lokey HLI has an Earnings ESP of +0.99% and carries a Zacks Rank of 3 at present. The Zacks Consensus Estimate for second-quarter 2025 earnings is pegged at $1.69, indicating a surge of 38.5% from the year-ago reported figure. HLI's earnings beat estimates in three of the last four quarters, while missing in one. Inter & Co. Inc. INTR has an Earnings ESP of +5.41% and a Zacks Rank of 3 at present. The Zacks Consensus Estimate for second-quarter 2025 earnings is pegged at 12 cents per share, indicating an increase of 33% from the year-ago reported figure. INTR's earnings beat estimates in two of the last four quarters, met in one and missed in one. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Euronet Worldwide, Inc. (EEFT): Free Stock Analysis Report Houlihan Lokey, Inc. (HLI): Free Stock Analysis Report Coinbase Global, Inc. (COIN): Free Stock Analysis Report Inter & Co. Inc. (INTR): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Globe and Mail
7 minutes ago
- Globe and Mail
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock
Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced that it has entered into definitive securities purchase agreements with several institutional and accredited investors for the sale of its Series A-3 Preferred Stock. The private placement closed on July 28, 2025. The Company issued and sold an aggregate of 4,500 shares of Series A-3 Preferred Stock, with a stated value of $1,000 per share, for aggregate gross proceeds of $4.5 million, before deducting placement agent fees and other offering expenses. The Series A-3 Preferred Stock is initially convertible into an aggregate of 1,607,143 shares of common stock of the Company at a conversion price of $2.80 per share, subject to adjustment in accordance with the terms of the Series A-3 Preferred Stock Certificate of Designation. Univest, LLC acted as the exclusive placement agent for the offering. The Company intends to use the net proceeds from the sale of the Series A-3 Preferred Stock for working capital purposes. The shares of Series A-3 Preferred Stock were offered and issued in a private placement under Section 4(a)(2) and/or Rule 506(b) of Regulation D under the Securities Act of 1933 and have not been registered under the Securities Act or applicable state securities laws. Accordingly, the shares of Series A-3 Preferred Stock and the underlying shares of common stock may not be offered or sold in the United States unless registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock underlying the Series A-3 Preferred Stock within 45 days after the closing date. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc. (NASDAQ: QLGN) is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases. The Company's pipeline includes QN-302, a selective G-quadruplex inhibitor targeting various tumor types including pancreatic cancer; QN-247, a nucleolin-targeting compound for hematologic malignancies; and a family of small-molecule RAS oncogene protein-protein interaction inhibitors. Each of these programs is designed to address areas of high unmet medical need, with the potential for orphan drug designation. Qualigen is committed to advancing its therapeutic pipeline to improve patient outcomes and create long-term value for shareholders. For more information about Qualigen Therapeutics, Inc., please visit Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on current expectations, estimates, assumptions, and projections about future events and involve inherent risks and uncertainties. These forward-looking statements include, but are not limited to, statements the filing of a resale registration statement, and the Company's future business plans and strategies. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'could,' 'would,' 'should,' 'continues,' and similar expressions are intended to identify such forward-looking statements. Actual results could differ materially from those projected due to a number of factors, including risks related to the Company's ability to successfully develop and commercialize its product candidates, regulatory developments, market conditions, the Company's ability to maintain compliance with Nasdaq listing requirements, and other risks described in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Globe and Mail
7 minutes ago
- Globe and Mail
Securities Fraud Investigation Into Charter Communications, Inc. (CHTR) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz announces an investigation of Charter Communications, Inc. ('Charter' or the 'Company') (NASDAQ: CHTR) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CHARTER COMMUNICATIONS, INC. (CHTR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 25, 2025, Charter released its second quarter 2025 financial results, reporting that total internet customers had declined by 117,000, compared to about 100,000 in the second quarter of 2024. The Company's total video customers also decreased by 80,000. On this news, Charter's stock price fell $70.25, or 18.5%, to close at $309.75 per share on July 25, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Charter securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
